Adjuvant treatment of node positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy
Treatment of breast cancer after the failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated
For the initial treatment of locally advanced or metastatic breast cancer
In combination with an athracycline in patients for whom anthracycline therapy is suitable, OR
In combination with trastuzumab, in patients who over-express human epidermal growth factor receptor 2 (HER-2) at a 3+ level as determined by immunohistochemistry and for whom anthracycline is not suitable
